INHIBITION OF TUMOR ANGIOGENESIS
INHIBITION OF TUMOR ANGIOGENESIS
复制标题
DOI：
10.1111/j.1749-6632.1994.tb24741.x
复制
发表时间：
1994-01-01
期刊：
影响因子：
--
通讯作者：
BREM, H
中科院分区：
文献类型：
--
作者：
SIPOS, EP;TAMARGO, RJ;BREM, H
实体瘤的指数生长依赖于诱导新血管生长，这是一个由肿瘤细胞产生的弥漫性血管生成因子介导的过程。通过抑制血管生成，现在有可能在实验动物中调节肿瘤的生长和转移。第一个描述的血管生成抑制剂是从软骨中提取的蛋白质。其他重要的抗血管生成药物包括血管抑制类固醇与肝素或肝素衍生物联合使用，以及烟霉素的合成衍生物。随着这些和其他血管抑制剂的作用机制的阐明，越来越明显的是，许多胶原代谢调节剂抑制血管生成，并可能提供临床有用的抗癌治疗。二甲胺四环素和其他具有抗胶原酶特性的四环素衍生物已被证明是血管生成的有效抑制剂。当这些药物与其他标准癌症疗法一起使用时，有助于延长患有实体瘤的实验动物的生存时间。对这些肿瘤进展的生物反应调节剂的进一步研究正在进行中，希望它们将为人类癌症提供有效的新治疗方法。
The exponential growth of solid tumors depends upon induction of new vessel growth, a process mediated by diffusable angiogenic factors produced by tumor cells. By inhibiting angiogenesis, it is now possible to modulate tumor growth and metastasis in laboratory animals. The first described inhibitor of angiogenesis was a protein derived from cartilage. Other important classes of antiangiogenic agents include angiostatic steroids combined with heparin or heparin derivatives, and the synthetic derivatives of fumigallin. As the mechanisms of action of these and other angiostatic agents are being elucidated, it is becoming apparent that many modulators of collagen metabolism inhibit angiogenesis and may offer clinically useful anticancer treatments. Minocycline and other tetracycline derivatives with anticollagenase properties have been shown to be potent inhibitors of angiogenesis. These agents, when administered with other standard cancer therapies, help prolong survival in laboratory animals with solid tumors. Further studies of these biologic response modifiers of tumor progression are under way in the hope that they will offer effective new treatments for cancer in humans.